Poprawa czasu przeżycia przy stosowaniu ipilimumabu u pacjentów z przerzutowym czerniakiem BACKGROUND An enchancment in general survival amongst sufferers with metastatic melanoma has been an elusive aim. On this section Three examine, ipilimumab–which blocks cytotoxic T-lymphocyte-associated antigen Four to potentiate an antitumor T-cell response–administered with or with out a glycoprotein 100 (gp100) peptide vaccine was in… Continue reading
